Andrew Hantel and Lauren Merz
Nov 20, 2025, 14:05
Andrew Hantel and Lauren Merz Had an Important Conversation About Appropriate Care
American Society of Hematology shared a post on LinkedIn:
“The Duffy-null phenotype is common among individuals of African, Middle Eastern, and North African ancestry, yet often misunderstood — leading to unnecessary procedures, inappropriate dose modifications, and exclusion from potentially life-saving therapies.
Join experts Drs. Andrew Hantel and Lauren Merz for an important conversation about appropriate care. Learn how Duffy-null affects absolute neutrophil counts (ANCs), clinical trial eligibility, and treatment decisions, including:
- How standard ANC cutoffs can disadvantage patients
- Implications for chemotherapy, immunosuppressive drugs, and clozapine
- The intersection of Duffy-null with recent updates to CTC AE grading
Listen now here.”
Read more here.
Stay informed with Hemostasis Today.
-
Sep 6, 2026, 14:15Listening to One Another Drives Innovation and Better Therapies in Hemophilia Care – Global Hemophilia Report
-
Sep 6, 2026, 14:12Filippo Crea: Exploring the Role of PAR4 in Platelet Hyperactivation in Hypertension
-
Sep 6, 2026, 14:10PALOP Coalition in Action: Practical Haemophilia Training in Angola – NNHF
-
Sep 6, 2026, 14:07Webinar on the Global Prevalence and Ethnic Diversity of von Willebrand Disease – EHC
-
Sep 6, 2026, 14:04Fatima Jamali: Advancements and Real-World Insights in Cell and Gene Therapy at MENA Rare Diseases 2026
-
Sep 6, 2026, 13:33Antoine Francis: Albumin – The Donor Patient Equation
-
Sep 6, 2026, 12:5810 Posts Not to Miss This Week
-
Sep 6, 2026, 12:38Parveen Yograj: Atrial Fibrillation More Than an Irregular Heartbeat
-
Sep 6, 2026, 12:38Marsha McLeod: The Safety Question Behind Canada’s High-Frequency Plasma Donations